Cargando…

Effect of low-dose exogenous surfactant on infants with acute respiratory distress syndrome after cardiac surgery: a retrospective analysis

BACKGROUND: Acute respiratory distress syndrome (ARDS) in infants undergoing cardiac surgery is associated with significant mortality and prolonged ventilation; surfactant administration may be a useful therapy. The purpose of this study is to evaluate the effect of low-dose exogenous surfactant the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Rongyuan, Wang, Xu, Li, Shoujun, Yan, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7407425/ https://www.ncbi.nlm.nih.gov/pubmed/32762672 http://dx.doi.org/10.1186/s12890-020-01251-2

Ejemplares similares

Exogenous surfactant therapy for acute respiratory distress in infancy
por: Moreno, M., et al.
Publicado: (1996)

Lung ultrasound to guide the administration of exogenous pulmonary surfactant in respiratory distress syndrome of newborn infants: A retrospective investigation study
por: Liu, Jing, et al.
Publicado: (2022)

Aerosolized Surfactant for Preterm Infants with Respiratory Distress Syndrome
por: Brasher, Mandy, et al.
Publicado: (2021)

Trial of aerosolised surfactant for preterm infants with respiratory distress syndrome
por: Jardine, Luke, et al.
Publicado: (2022)

Exogenous pulmonary surfactant for acute respiratory distress syndrome in adults: A systematic review and meta-analysis
por: ZHANG, LI-NA, et al.
Publicado: (2013)

Surfactants in Acute Respiratory Distress Syndrome in Infants and Children: Past, Present and Future
por: Amigoni, Angela, et al.
Publicado: (2017)

Early Surfactant Therapy for Respiratory Distress Syndrome in Very Preterm Infants
por: Cucerea, Manuela, et al.
Publicado: (2023)

Effect of surfactant dose on outcomes in preterm infants with respiratory distress syndrome: the OPTI-SURF study protocol
por: Goss, Kevin Colin William, et al.
Publicado: (2020)

Exogenous pulmonary surfactant for the treatment of adult patients with acute respiratory distress syndrome: results of a meta-analysis
por: Davidson, Warren J, et al.
Publicado: (2006)

Exogenous Surfactant Therapy in Acute Lung Injury/Acute Respiratory Distress Syndrome: The Need for a Revised Paradigm Approach
por: Dushianthan, Ahilanandan, et al.
Publicado: (2012)

FiO(2) Before Surfactant, but Not Time to Surfactant, Affects Outcomes in Infants With Respiratory Distress Syndrome
por: Kruczek, Piotr, et al.
Publicado: (2021)

The Role of Surfactant in Respiratory Distress Syndrome
por: Ma, Christopher Cheng-Hwa, et al.
Publicado: (2012)

Surfactant preparations for preterm infants with respiratory distress syndrome: past, present, and future
por: Jeon, Ga Won
Publicado: (2019)

Practical considerations when administering surfactants to preterm infants with respiratory distress syndrome
por: Jo, Heui Seung
Publicado: (2019)

Profound Effect of Pulmonary Surfactant on the Treatment of Preterm Infants with Respiratory Distress Syndrome
por: Liu, Lin, et al.
Publicado: (2022)

Surfactant alteration and replacement in acute respiratory distress syndrome
por: Günther, Andreas, et al.
Publicado: (2001)

Efficacy of Surfactant-TA, Calfactant and Poractant Alfa for Preterm Infants with Respiratory Distress Syndrome: A Retrospective Study
por: Jeon, Ga Won, et al.
Publicado: (2015)

Surfactant proteins gene variants in premature newborn infants with severe respiratory distress syndrome
por: Somaschini, Marco, et al.
Publicado: (2017)

Transient intubation for surfactant administration in the treatment of respiratory distress syndrome in extremely premature infants
por: Koh, Ji Won, et al.
Publicado: (2018)

Alternative Methods of Surfactant Administration in Preterm Infants with Respiratory Distress Syndrome: State of the Art
por: Erdeve, Ömer, et al.
Publicado: (2021)

Respiratory distress syndrome in preterm infants of less than 32 weeks: What difference does giving 100 or 200 mg/kg of exogenous surfactant make?
por: Lanciotti, Lucia, et al.
Publicado: (2022)

Surfactant therapy in preterm infants with respiratory distress syndrome and in near-term or term newborns with acute RDS
por: Ramanathan, R
Publicado: (2006)

Use of exogenous pulmonary surfactant in acute respiratory distress syndrome (ARDS): Role in SARS-CoV-2-related lung injury
por: Cattel, Francesco, et al.
Publicado: (2021)

Clinical review: Exogenous surfactant therapy for acute lung injury/acute respiratory distress syndrome - where do we go from here?
por: Dushianthan, Ahilanandan, et al.
Publicado: (2012)

Prone Ventilation in the Management of Infants With Acute Respiratory Distress Syndrome After Complex Cardiac Surgery
por: Balachandran, Rakhi, et al.
Publicado: (2012)

Effects of bovine lipid extract surfactant administration in preterm infants treated for respiratory distress syndrome
por: Stockley, Elizabeth, et al.
Publicado: (2018)

Surfactant replacement therapy for respiratory distress syndrome in preterm infants: United Kingdom national consensus
por: Banerjee, Sujoy, et al.
Publicado: (2019)

Comparing the clinical and economic efficiency of four natural surfactants in treating infants with respiratory distress syndrome
por: Izadi, Reyhane, et al.
Publicado: (2023)

Efficacy of exogenous surfactant in adult patients with acute respiratory failure
por: Tiruvoipati, R, et al.
Publicado: (2006)

Gender-related efficacy of pulmonary surfactant in infants with respiratory distress syndrome: A STROBE compliant study
por: Chen, Chen, et al.
Publicado: (2018)

Lung Mechanics in COVID-19 Resemble Respiratory Distress Syndrome, Not Acute Respiratory Distress Syndrome: Could Surfactant Be a Treatment?
por: Koumbourlis, Anastassios C., et al.
Publicado: (2020)

Surfactant replacement therapy in acute respiratory distress syndrome from viral pneumonia
por: Putz, G., et al.
Publicado: (1996)

The Role of Pulmonary Surfactants in the Treatment of Acute Respiratory Distress Syndrome in COVID-19
por: Wang, Shengguang, et al.
Publicado: (2021)

Efficacy of pulmonary surfactant combined with high-dose ambroxol hydrochloride in the treatment of neonatal respiratory distress syndrome
por: Xiang, Jiajun, et al.
Publicado: (2019)

Outcome of Very Premature Newborn Receiving an Early Second Dose of Surfactant for Persistent Respiratory Distress Syndrome
por: Greiner, Eva, et al.
Publicado: (2021)

Effects of less invasive surfactant administration versus intubation-surfactant-extubation on bronchopulmonary dysplasia in preterm infants with respiratory distress syndrome: a single-center, retrospective study from China
por: Xu, Chun-cai, et al.
Publicado: (2022)

Single Nucleotide Polymorphisms Interactions of the Surfactant Protein Genes Associated With Respiratory Distress Syndrome Susceptibility in Preterm Infants
por: Amatya, Shaili, et al.
Publicado: (2021)

The Influence of the Technique of Surfactant Administration (LISA vs INSURE) on the Outcomes of Respiratory Distress Syndrome Treatment in Preterm Infants
por: Kaniewska, Urszula, et al.
Publicado: (2019)

Comparative efficacy of pulmonary surfactant in respiratory distress syndrome in preterm infants: a Bayesian network meta-analysis
por: Qiu, Caihong, et al.
Publicado: (2020)

Low-dose CT for quantitative analysis in acute respiratory distress syndrome
por: Vecchi, Vittoria, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_vms3nao1moid8nai0ab674ibvq